Previous 10 | Next 10 |
Shares of 23andMe (NASDAQ: ME) dropped 29.1% in November, according to data from S&P Global Market Intelligence . The DNA testing and therapeutics company reported a disappointing quarterly report and likely fell victim to the sell-off in high-growth names last month. On...
SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the company’s new Chief Scientific Officer. In th...
23andMe (NASDAQ:ME) plans to redeem all of its outstanding warrants to purchase shares for a redemption price of $0.10 per Public Warrant. The company will redeem all of its outstanding warrants to purchase Class A common stock that were issued under the Warrant Agreement in a private pl...
SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of ...
David Einhorn's 13F stock portfolio value decreased from $1.59B to $1.49B this quarter. Greenlight increased The ODP Group, LivaNova plc, and Sonos while reducing Concentrix and AerCap Holdings. The largest three positions are at ~44% of the portfolio. As of Q3 2021, the overall p...
23andMe Holding (ME -10.9%) has recorded the sharpest intra-day loss since its IPO in June after Bank of America downgraded the stock to Neutral from Buy on valuation. Noting over ~70% gain in 23andMe (NASDAQ:ME) shares over the past month, the analysts led by Daniel Grosslight argu...
Shares of genetic data miner 23andMe Holding (NASDAQ: ME) had a good week last week, surging more than 13% in response to a positive second-quarter 2022 earnings report Thursday. But as I warned at the time , the news wasn't quite as good as it looked, and 23andMe's gains st...
Shares of genetic data miner 23andMe Holding (NASDAQ: ME) had surged 10.7% as of 12:45 p.m. EST Thursday in response to a mixed fiscal second-quarter 2022 earnings report featuring weaker revenue than predicted -- but a much lower loss than feared. Heading into the quarter, ...
23andMe Holding Co. (ME) Q2 2021 Earnings Conference Call November 10, 2021, 16:30 ET Company Participants Wade Walke - VP, IR Anne Wojcicki - Co-Founder, CEO, President & Director Steven Schoch - Chief Financial & Accounting Officer Kenneth Hillan - Head, Therapeutics Conference Call...
23andMe (NASDAQ:ME): Q2 GAAP EPS of -$0.04 beats by $0.07. Revenue of $55.2M (+6.6% Y/Y) misses by $0.51M. Press Release For further details see: 23andMe EPS beats by $0.07, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...